U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07385430) titled 'Study of LGW16-03 To Identify Nerves' on Jan. 13.
Brief Summary: The primary goal of this study is to determine the safety and tolerability of LGW16-03, a novel nerve-labeling fluorophore, in participants undergoing open-field orthopaedic surgery. Secondary goals include: 1) identifying the lowest dose without adverse events that provides peak florescence imaging contrast, and 2) characterizing the pharmacokinetics of LGW16-03.
Participants will receive a one-time intravenous infusion of the investigational drug (LGW16-03) prior to their planned surgery. Participants' vitals will be closely monitored and will have blood samples take...